Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.357
+0.004 (1.05%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Theriva Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 6.42 | 6.7 | 7.78 | 7.57 | 6.47 | |
| Research & Development | 8.6 | 12.03 | 14.31 | 11.72 | 7.8 | |
| Operating Expenses | 15.02 | 18.73 | 22.09 | 19.29 | 14.27 | |
| Operating Income | -15.02 | -18.73 | -22.09 | -19.29 | -14.27 | |
| Interest & Investment Income | 0.29 | 0.7 | 1.44 | 0.51 | 0.01 | |
| Currency Exchange Gain (Loss) | 0.03 | -0 | 0 | -0.04 | - | |
| EBT Excluding Unusual Items | -14.71 | -18.04 | -20.65 | -18.82 | -14.27 | |
| Merger & Restructuring Charges | - | - | - | -0.2 | - | |
| Impairment of Goodwill | - | -5.59 | - | - | - | |
| Other Unusual Items | -9.03 | -0.7 | 0.66 | -2.09 | - | |
| Pretax Income | -23.74 | -25.65 | -19.99 | -21.11 | -14.27 | |
| Income Tax Expense | - | - | -1.64 | -1.43 | - | |
| Earnings From Continuing Operations | -23.74 | -25.65 | -18.35 | -19.69 | -14.27 | |
| Minority Interest in Earnings | - | - | - | - | 0 | |
| Net Income | -23.74 | -25.65 | -18.35 | -19.69 | -14.27 | |
| Preferred Dividends & Other Adjustments | 1.51 | - | - | 0.34 | 8.92 | |
| Net Income to Common | -25.25 | -25.65 | -18.35 | -20.03 | -23.19 | |
| Shares Outstanding (Basic) | 12 | 1 | 1 | 1 | 0 | |
| Shares Outstanding (Diluted) | 12 | 1 | 1 | 1 | 0 | |
| Shares Change (YoY) | 800.56% | 109.24% | 5.09% | 25.76% | 541.07% | |
| EPS (Basic) | -2.08 | -19.03 | -28.48 | -32.66 | -47.57 | |
| EPS (Diluted) | -2.08 | -19.03 | -28.48 | -32.66 | -47.57 | |
| Free Cash Flow | -16.7 | -16.94 | -19.2 | -19.2 | -12.9 | |
| Free Cash Flow Per Share | -1.38 | -12.56 | -29.80 | -31.31 | -26.47 | |
| EBITDA | -14.91 | -18.59 | -21.96 | -19.21 | -14.19 | |
| D&A For EBITDA | 0.11 | 0.14 | 0.14 | 0.09 | 0.09 | |
| EBIT | -15.02 | -18.73 | -22.09 | -19.29 | -14.27 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.